Impact of cause of death adjudication on the results of the European prostate cancer screening trial-Reference-Cited by-同舟云学术

Impact of cause of death adjudication on the results of the European prostate cancer screening trial

Published:2016-11-17 Issue:1 Volume:116 Page:141-148
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Walter Stephen D, ,de Koning Harry J,Hugosson Jonas,Talala Kirsi,Roobol Monique J,Carlsson Sigrid,Zappa Marco,Nelen Vera,Kwiatkowski Maciej,Páez Álvaro,Moss Sue,Auvinen Anssi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016378.pdf

Reference34 articles.

1. Allemani C, Weir HK, Carrera H, Harewood R, Spika D, Wang X, Bannon Finian, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP the CONCORD Working Group (2015) Global surveillance of cancer survival 1995–2009 (CONCORD-2). Lancet 385: 977–1010.

2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC PLCO Project Team (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104: 125–132.

3. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A (2003) Contamination by opportunistic screening in the ERSPC. BJU Int 92 (Suppl 2): 97–100.

4. de Koning HJ, Blom J, Merkelbach JW, Raaijmakers R, Verhaegen H, Van Vliet P, Nelen V, Coebergh JW, Hermans A, Ciatto S, Mäkinen T (2003) Determining the cause of death in randomised screening trials for prostate cancer. BJU Int 92 (Suppl 2): 71–78.

5. Doria-Rose VP, Marcus PM, Miller AB, Bergstralh EJ, Mandel JS, Tockman MS, Prorok PC (2010) Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. Clin Trials 7: 69–77.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjudication of Self-reported Symptomatic Stone Recurrence in the Prevention of Urinary Stones With Hydration Trial;Urology;2024-09

2. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer;BJU International;2024-05-09

3. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden;BJU International;2022-09-26

4. Reply to Takeshi Takahashi’s Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703–711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?;European Urology;2022-01

5. Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer;European Urology Open Science;2021-12